Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

Autor: Fässler, Mirjam, Diem, Stefan, Mangana, Joanna, Hasan Ali, Omar, Berner, Fiamma, Bomze, David, Ring, Sandra, Niederer, Rebekka, Del Carmen Gil Cruz, Cristina, Pérez Shibayama, Christian Ivan, Krolik, Michal, Siano, Marco, Joerger, Markus, Recher, Mike, Risch, Lorenz, Güsewell, Sabine, Risch, Martin, Speiser, Daniel E, Ludewig, Burkhard, Levesque, Mitchell P, Dummer, Reinhard, Flatz, Lukas

Publikováno v: Fässler, Mirjam; Diem, Stefan; Mangana, Joanna; Hasan Ali, Omar; Berner, Fiamma; Bomze, David; Ring, Sandra; Niederer, Rebekka; Del Carmen Gil Cruz, Cristina; Pérez Shibayama, Christian Ivan; Krolik, Michal; Siano, Marco; Joerger, Markus; Recher, Mike; Risch, Lorenz; Güsewell, Sabine; Risch, Martin; Speiser, Daniel E; Ludewig, Burkhard; Levesque, Mitchell P; ... (2019). Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. Journal for immunotherapy of cancer, 7(1), p. 50. BioMed Central 10.1186/s40425-019-0523-2
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol. 7, no. 1, pp. 50

Background Long-term survival of stage IV melanoma patients has improved significantly with the development of immune checkpoint inhibitors (CIs). Reliable biomarkers to predict response and clinical outcome are needed. Methods We investigated the ro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c0383a55b6649492b2f23f1522734b4
https://boris.unibe.ch/174992/1/50.full.pdf